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Inflammatory responses need to be
tightly controlled to maintain
homeostasis. Stehlik and colleagues
demonstrate that the PYRIN domain-only
protein POP1 inhibits ASC-containing
inflammasome assembly and
consequently caspase-1 activation, IL-1b
and IL-18 release, pyroptosis, and the
release of ASC particles in macrophages.
Importantly, transgenic POP1 expression
protects mice from systemic
inflammation.
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In response to infections and tissue damage, ASC-
containing inflammasome protein complexes are
assembled that promote caspase-1 activation,
IL-1b and IL-18 processing and release, pyroptosis,
and the release of ASC particles. However, excessive
or persistent activation of the inflammasome causes
inflammatory diseases. Therefore, a well-balanced
inflammasome response is crucial for the mainte-
nance of homeostasis. We show that the PYD-only
protein POP1 inhibited ASC-dependent inflamma-
some assembly by preventing inflammasome nucle-
ation, and consequently interfered with caspase-1
activation, IL-1b and IL-18 release, pyroptosis, and
the release of ASC particles. There is no mouse
ortholog for POP1, but transgenic expression of
human POP1 in monocytes, macrophages, and
dendritic cells protected mice from systemic inflam-
mation triggered by molecular PAMPs, inflamma-
some component NLRP3 mutation, and ASC danger
particles. POP1 expression was regulated by TLR
and IL-1R signaling, and we propose that POP1 pro-
vides a regulatory feedback loop that shuts down
excessive inflammatory responses and thereby pre-
vents systemic inflammation.
INTRODUCTION
Inflammation is an essential and tightly controlled process
initiated by the innate immune system in response to infection
and tissue damage and is responsible for pathogen clearance,
wound healing, and restoring homeostasis. It is triggered by
the sensing of pathogen-associatedmolecular patterns (PAMPs)
or damage-associated molecular patterns (DAMPs or danger
signals) by germline-encoded pattern recognition receptors
(PRRs). Particularly, cytosolic PRRs of the AIM2-like receptor264 Immunity 43, 264–276, August 18, 2015 ª2015 Elsevier Inc.(ALR) and Nod-like receptor (NLR) families facilitate the activa-
tion of the pro-inflammatory caspase-1 within large macro-
molecular protein complexes in macrophages, referred to as
inflammasomes. Inflammasomes promote the proteolytic matu-
ration and release of the leaderless pro-inflammatory cytokines
interleukin (IL)-1b and IL-18 and the induction of pyroptotic cell
death, which causes the release of IL-1a and HMGB1 (Martinon
et al., 2002; Khare et al., 2010; Wen et al., 2013). Inflammasomes
are composed of a sensory PRR,which is linked to caspase-1 via
the adaptor protein ASC (Srinivasula et al., 2002; Stehlik et al.,
2003a; Martinon et al., 2002). This complex exhibits specific
protein-protein interactions, which are mediated by homotypic
PYRIN domain (PYD) interactions between PRRs and ASC and
by homotypic caspase recruitment domain (CARD) interactions
between ASC and pro-caspase-1. Within this protein complex,
pro-caspase-1 is activated by induced proximity-mediated olig-
omerization (Martinon et al., 2002; Lu et al., 2014). The underlying
assembly mechanism of this ternary complex has recently been
delineated and indicates that PRR activation triggers prion-like,
self-perpetuating ASC polymerization into filaments, which is
initialized by PRR-induced ASCPYD nucleation (Cai et al., 2014;
Lu et al., 2014; Franklin et al., 2014; Dorfleutner et al., 2015).
PRRs localize to the end of the hollow ASC filaments and allow
efficient self-propagation of the ASCPYD, whereby the ASCCARD
is flexibly linked to the outside of the filaments, allowing recruit-
ment and clustering of pro-caspase-1 (Lu et al., 2014). Eventu-
ally, these filaments can assemble into a spherical structure,
where caspase-1 is placed in the hollow core (Man et al.,
2014). Thus, the PYD is essential for inflammasome assembly
after activation of NLRP3 and other PYD-containing PRRs, and
disassembly of this ternary signaling complex is required for its
termination. NLRP3 is one of the best-studied inflammasome-
activating PRRs and the NLRP3 inflammasome is regulated by
a two-step mechanism, referred to as priming and activation
(Khare et al., 2010). After priming with LPS or other NF-kB-
inducing signals, NLRP3 is activated in a second step by a
wide variety of PAMPs that cause potassium (K+) efflux,
including exogenous ATP, nigericin, and uric acid crystals, as
well as environmental and endogenous mediators released
in response to stress and tissue damage (Khare et al., 2010;
Mun˜oz-Planillo et al., 2013). Besides inflammasome-linked
cytokines, oligomeric ASC particles are also released and
phagocytized by neighboring cells to perpetuate inflammasome
responses (Franklin et al., 2014; Baroja-Mazo et al., 2014). Over-
all, inflammasomes play an essential role in host defense.
However, impaired inflammasome activation results in failure
to restrict colitogenic microbiota species and subsequently
promotesmetabolic dysfunction. In contrast, constitutive inflam-
masome activation through disease-associated mutations in
NLRP3 promotes excessive IL-1b release and causes inflamma-
tory diseases, including Cryopyrinopathies (or Cryopyrin-associ-
ated periodic syndromes; CAPS) (Henao-Mejia et al., 2012;
Hoffman and Brydges, 2011). Therefore, a controlled and well-
balanced inflammasome response is essential for maintaining
homeostasis. However, the molecular mechanisms regulating
assembly and disassembly of inflammasomes are largely un-
known. We discovered a family of PYD-only proteins (POPs)
that are encoded in humans but not in mice (Stehlik and Dorfleut-
ner, 2007; Khare et al., 2014; Stehlik et al., 2003b; Dorfleutner
et al., 2007a, 2007b; Bedoya et al., 2007; Johnston et al.,
2005). We recently demonstrated that POP3 functions as a spe-
cific inhibitor for ALR inflammasomes (Khare et al., 2014). POP3
binds to the PYD of ALRs, but not to ASC or NLRs, and thereby
prevents ALR interactions with the inflammasome adaptor ASC.
However, the function of endogenous POP1 (PYD-containing 1,
PYDC1) has not yet been established. POP1 is highly similar to
the PYD of ASC and in vitro overexpression experiments showed
that POP1 interacts with the PYD of ASC; however, its role in vivo
is unknown.
Herewe report that POP1 functions in an IL-1b-induced regula-
tory loop to inhibit the assembly and consequently the activity
of ASC-containing inflammasomes by preventing nucleation of
ASC. POP1 also prevented the release of oligomeric ASC danger
particles, and incorporation of POP1 into ASC particles rendered
them inactive, thereby preventing self-perpetuation of inflam-
masome responses in neighboring cells. To demonstrate the
importance of inflammasomes particularly in monocytes and
macrophages,weengineeredmice thatusually lackPOP1 to spe-
cifically express transgenic POP1 in monocytes, macrophages,
and DCs. We used the NLRP3 inflammasome as an example to
demonstrate that transgenic POP1 expression in the monocyte-
macrophage-DC lineage was sufficient to blunt excessive sys-
temic inflammation in response to PAMPs, ASC danger particles,
and CAPS-associated mutations. Interestingly, CAPS patients
exhibited reduced POP1 expression, suggesting that impaired
POP1 expression might contribute to excessive inflammasome-
driven inflammation. Our data reveal a mechanism by which hu-
man inflammasome assembly is regulated and detail how healthy
tissue puts the brakes on inflammasome-induced systemic
inflammation. In addition, our results emphasize the crucial role
of the monocyte-macrophage-DC lineage in this response.
RESULTS
POP1 Inhibits Inflammasome-Mediated Cytokine
Release in Human Macrophages
To investigate the role of POP1 in inflammasome signaling, we
established stable shRNA-mediated POP1 silencing in human
monocytic THP-1 cells (shPOP1 THP-1). POP1 knockdown (viatwo different shRNAs causing elevated IL-1b release in response
to LPS and POP1 silencing) was confirmed by qPCR (Figure 1A).
Similarly, siRNA-mediated silencing of POP1 in primary human
macrophages resulted in elevated IL-1b and IL-18, but not
IL-6, release in response to LPS. POP1 silencing was again
confirmed by qPCR (Figure 1B). Conversely, THP-1 cells stably
expressing GFP-POP1 displayed diminished IL-1b secretion in
response to LPS and also in response to non-canonical inflam-
masome activation with LPS transfection or cytosolic delivery
of LPS with cholera toxin subunit B (CTB) (Figure 1C). Cytokine
release after non-canonical inflammasome activation requires
NLRP3. Consistently, POP1 blocked IL-1b release after NLRP3
inflammasome activation with nigericin, calcium pyrophosphate
dehydrate (CPPD) crystals, or K+ depletion. Furthermore, POP1
blocked IL-1b release after AIM2 and NLRC4 activation with
poly(dA:dT) or flagellin transfection, respectively (Figure 1D),
and POP1 expression was confirmed by qPCR (Figure 1E).
Hence, POP1 inhibits inflammasome-dependent cytokine
release. Comparable results were also obtained for myc-tagged
POP1, thus establishing that the GFP tag does not affect the
function of POP1 (Figure S1A).
POP1 Impairs ASCPYD Nucleation and Caspase-1
Activation in Human Macrophages
Caspase-1 activation in canonical inflammasomes of macro-
phages is required for IL-1b and IL-18 release and for pyroptosis.
Therefore, we determined caspase-1 activity in the presence
and absence of POP1. Treatment of Pam3CSK4-primed shPOP1
knockdown cells with nigericin resulted in elevated active
caspase-1 p10 and mature IL-1b in culture supernatants when
compared to control THP-1 cells (Figure 2A). Further, intracel-
lular caspase-1 activation was also augmented in shPOP1
THP-1 compared to control THP-1, as shown by caspase-1
FLICA assay (Figure 2B). Conversely, expression of GFP-POP1
in primed THP-1 cells showed drastically reduced caspase-1
activity in response to nigericin compared to GFP THP-1 cells
(Figure 2C). Consequently, POP1 expression also caused
reduced pyroptosis, as determined by LDH release (Figure 2D).
TLR-mediated priming is necessary for NLRP3 inflammasome
activation (Bauernfeind et al., 2009; Juliana et al., 2012; Schroder
et al., 2012; Lin et al., 2014). However, stable POP1 expression in
THP-1 cells did not affect transcription of IL1B (Figure S1B) and
resulted in mild increased transcription of NLRP3 or PYCARD
(ASC) in response to LPS (Figure S1C), and contrary to transient
overexpression in epithelial cell lines (Stehlik et al., 2003b), stable
POP1 expression also did not affect phosphorylation of IkBa
(Figure S1D). Furthermore, silencing of POP1 in THP-1 cells
also did not affect transcription of PYCARD and NLRP3 (Fig-
ure S1E). Thus, POP1 seems to directly regulate inflammasome
assembly or activation in macrophages. Recruitment of ASC to
upstream sensors is essential for inflammasome activation and
we hypothesized that POP1 interferes with this interaction.
POP1 specifically bound to endogenous ASC, but not to the
PYD-containing PRRs NLRP3 and AIM2 in LPS-primed THP-1
cells (Figure 2E). Binding of ASC to NLRP3 induces ASCPYD
nucleation, which provides the oligomeric platform essential
for caspase-1 activation (Cai et al., 2014; Lu et al., 2014). There-
fore, we hypothesized that POP1 prevents ASCPYD-NLRP3PYD
interactions and thus ASCPYD nucleation (Chu et al., 2015).Immunity 43, 264–276, August 18, 2015 ª2015 Elsevier Inc. 265
Figure 1. POP1 Inhibits the NLRP3 Inflammasome in Human Macrophages
(A) THP-1 cells stably expressing shRNAs targeting POP1 (POP1#1, #2) or a scrambled Ctrl were analyzed by real-time PCR for POP1 transcripts and for IL-1b
release in culture supernatants (SN) in untreated cells (Ctrl) or in response to LPS.
(B) Primary human macrophages transfected with a scrambled Ctrl or a POP1-specific siRNA were analyzed for POP1 transcripts by real-time PCR and culture
SN for IL-1b, IL-18, and IL-6 release in response to LPS.
(C and D) Culture SN from THP-1 cells stably expressing GFP or GFP-POP1were analyzed for IL-1b release by ELISA in untreated cells (Ctrl) or in response to LPS
treatment, LPS transfection, or incubation with LPS complexed with CTB (C) and nigericin or CPPD treatment or K+ depletion in LPS-primed cells or transfection
of poly(dA:dT) or flagellin (D).
(E) Real-time PCR of POP1 transcripts in above cells.
Data are representative of two (A) or three (B–E) replicates; error bars represent SEM. *p = 0.0009, **p = 0.0128, ***p < 0.0001, ****p < 0.0001 in (A); *p = 0.0284,
**p = 0.0315, ***p = 0.0001 in (B); *p < 0.0001, **p < 0.0001, ***p < 0.0001 in left panel of (D); *p < 0.0001, **p < 0.0001 in right panel of (D); and *p = 0.0024,
**p = 0.0022, ***p = 0.0139 in (E); all two-tailed unpaired t test. See also Figure S1A.Indeed, the nigericin-induced interaction of NLRP3 and ASC
was abolished in LPS-primed GFP-POP1 THP-1 cells, indicating
that POP1 might prevent NLRP3-mediated ASC nucleation
(Figure 2F). Upon ASC nucleation, the ASCPYD polymerizes in
a prion-like self-perpetuating manner that further promotes
caspase-1 activation (Lu et al., 2014). Because ASC-ASC,
ASC-POP1, and ASC-NLRP3 interactions utilize the same key
residues (Vajjhala et al., 2012), POP1 binding to the ASCPYD
could also directly prevent ASCPYD self-polymerization. Surpris-
ingly, POP1 expression in HEK293 cells did not impair the
ASCPYD self-interaction, as determined by in coIP experiments
between Myc-ASC and HA-ASCPYD (Figure S1F). However,
overexpression in HEK293 cells might lead to inaccurate results.
Our data indicate that, in the context of PRR-mediated inflam-
masome activation, POP1 prevents the essential ASC nucleation
step in human macrophages, which is required for inflamma-
some assembly.
POP1 Prevents Caspase-1 Activation and Cytokine
Release in Mouse Macrophages
Because the genes for all POPs, including POP1, are absent
in mice (Stehlik and Dorfleutner, 2007; Khare et al., 2014),266 Immunity 43, 264–276, August 18, 2015 ª2015 Elsevier Inc.we generated GFP-POP1 transgenic (TG) mice. Caspase-1 is
essential for IL-1b and IL-18 release in monocytes and macro-
phages and we detected POP1 expression in CD68+ macro-
phages in inflamed lung tissue (Figure S2A). Therefore, to limit
POP1 expression to macrophages, we used the hCD68/IVS-1
promoter/enhancer (Iqbal et al., 2014; Khare et al., 2014;
Gough et al., 2001) for GFP-POP1 expression in TG mice. We
confirmed POP1 expression specifically in CD68-POP1 TG
but not in wild-type (WT) mice by qPCR analysis of whole blood
cell RNA (Figure S2B). Accordingly, we also detected POP1
expression in transgenic POP1 bone-marrow-derived macro-
phages (BMDMs) by immunoblot (Figure 3A). Human and
mouse ASCPYD have a high degree of homology (Figure S2C)
and therefore it was not surprising that, similar to human
ASC in THP-1 cells, POP1 also interacted with mouse ASC,
but not NLRP3 or AIM2 in BMDMs (Figure 3B). ASC polymeri-
zation can be captured by non-reversible cross-linking and
functions as a read-out for inflammasome activation (Fer-
nandes-Alnemri et al., 2007), which was markedly reduced in
LPS-primed and ATP-treated POP1 BMDMs compared to WT
BMDMs (Figure 3C). Consequently, POP1 BMDMs lacked
active caspase-1 p10 and mature IL-1 b in culture supernatants
Figure 2. POP1 Impairs Inflammasome Nucleation in Human Macrophages
(A and B) Pam3CSK4-primed THP-1 cells stably expressing shRNA#1 targeting POP1 or a scrambled Ctrl were treated with nigericin and total cell lysates (TCL)
and culture supernatants (SN) were analyzed for caspase-1 and IL-1b by immunoblot (A) or active caspase-1 by flow cytometry (B).
(C) LPS-primed THP-1 cells expressing GFP or GFP-POP1 were treated with nigericin and active caspase-1 was determined by flow cytometry.
(D) LPS-primed THP-1 cells expressing GFP or GFP-POP1 were treated with nigericin or CPPD crystals, and LDH release was quantified in culture supernatants.
*p = 0.001, **p = 0.0004 by two-tailed unpaired t test.
(E) Interaction of GST-POP1 with endogenous ASC in THP-1 TCL using GST as negative control and showing 10% TCL as input. Asterisk (*) marks a degradation
product of GST-POP1.
(F) Immunoprecipitation (IP) of proteins with antibodies to ASC or control immunoglobulin G (IgG) from LPS-primed and nigericin-treated THP-1 cells stably
expressing GFP or GFP-POP1, followed by immunoblot analysis alongside TCL.
Data are representative of two replicates; error bars represent SEM. See also Figures S1B–S1F.of LPS/ATP-treated cells to a similar extent as the caspase-1
inhibitor zYVAD-fmk (Figure 3D). Reduced caspase-1 activity
was also detected by flow cytometry in intact cells (Figure 3E),
indicating that POP1 also inhibits caspase-1 activation in
mouse macrophages.
As expected from impaired caspase-1 activation, LPS/ATP-
treated POP1 BMDMs also displayed significantly reduced
levels of IL-1b, IL-1a, and IL-18 in culture supernatants by ELISA.
However, secretion of TNF-a, which occurs independently of
caspase-1, was not affected (Figure 3F). Significantly, reduced
IL-1b release in POP1 BMDMs was comparable to Pycard/
BMDMs and Nlrp3/ BMDMs (Figure 3G). K+ efflux is the unify-
ing mechanism of NLRP3 activation in BMDMs (Mun˜oz-Planillo
et al., 2013), and culturing POP1 BMDMs in K+-free medium
showed impaired IL-1b release compared to WT BMDMs (Fig-
ure 3H). Similarly, peritoneal POP1 macrophages (POP1 PMs)
showed impaired IL-1b release in response to activation of
ASC-dependent inflammasomes containing NLRP3 with ATP,
AIM2 with poly(dA:dT), and NLRC4 with flagellin (Figure 3I).
POP1 BMDMs also showed reduced LDH release, and thus py-
roptosis, when compared to WT BMDMs in response to NLRP3activation (Figure 3J), but did not reveal any altered LPS-induced
activation of NF-kB, p38, JNK, or ERK (Figure S2D) or altered
transcription of Il1b, Il18, Pycard, and Nlrp3 (Figure S2E),
ruling out POP1 effects on inflammasome priming in mouse
macrophages. Collectively, these data indicate that POP1 im-
pairs assembly of the NLRP3 inflammasome in human and
mousemacrophages by impairing the PRR-mediated nucleation
of ASC and consequently the release of inflammasome-depen-
dent cytokines.
Monocyte-Macrophage-DC-Specific Expression of
POP1 Ameliorates LPS-Induced Peritonitis
NLRP3 senses endogenous danger signals and PAMPs and
promotes inflammatory responses that can be detrimental
to the host. We therefore used the NLRP3 inflammasome to
investigate the role of POP1 in vivo. To initially characterize
the CD68-POP1 TG mice, we analyzed peripheral blood, which
revealed POP1 expression selectively in monocytes (Figures
4A and S3), with equal expression in classical Ly6ChiCD43–, in-
termediate Ly6CintCD43+, and non-classical Ly6CloCD43+
monocytes (Figure S4A). POP1 was also expressed in myeloidImmunity 43, 264–276, August 18, 2015 ª2015 Elsevier Inc. 267
Figure 3. POP1 Inhibits the NLRP3 Inflammasome in Mouse Macrophages
(A) Immunoblot of POP1 expression in BMDMs using a GFP antibody.
(B) Interaction of GST-POP1 with endogenous ASC from LPS-primed BMDM total cell lysates (TCL) using GST as negative control and showing 10% TCL as
input. Asterisk (*) marks a degradation product of GST-POP1.
(C) Immunoblot analysis of ASC polymerization (oligomerization) in untreated or LPS/ATP-treated wild-type (WT) and POP1 BMDMs after cross linking of pellets
(P) and in TCL.
(D) Immunoblot analysis of caspase-1 and IL-1b in culture SN of LPS/ATP-treated WT and POP1 BMDMs. Pro-caspase-1 expression in TCL confirms
equal loading.
(E) Flow cytometric quantification of active caspase-1 in WT and POP1 BMDMs in response to LPS/ATP.
(F) Analysis of culture supernatants (SN) for IL-1b, IL-18, IL-1a, and TNF-a by ELISA in LPS/ATP-treated WT and POP1 BMDMs.
(G) Analysis of culture SN for IL-1b by ELISA in LPS-primed and ATP-treated WT, POP1, Pycard/, and Nlrp3/ BMDMs.
(H) LPS-primed WT and POP1 BMDMs cultured in K+ depleted medium
(I) WT and POP1 PMs treated with LPS/ATP or transfected with flagellin or poly(dA:dT).
(J) LPS-primed WT and POP1 BMDMs were treated with nigericin or CPPD crystals and released LDH in culture SN was quantified.
Data are representative of four (A, H, I) or two (B–G, J) replicates; error bars represent SEM. *p = 0.0027, **p = 0.003, ***p = 0.0403 in (F); *p = 0.0214, **p = 0.0043,
***p = 0.0052 in (G); *p = 0.01 in (H); *p = 0.0009, **p < 0.0001 in (I); and *p < 0.0001 in (J); all two-tailed unpaired t test. See also Figure S2.precursors (MPs), macrophage and DC precursors (MDPs),
and common DC precursors (CDPs) in the bone marrow (Fig-
ures S4B and S4C), large peritoneal macrophages (LPMs),
small peritoneal macrophages (SPMs), and peritoneal DCs
(Figures S4D and S4E), as well as in splenic red pulp macro-
phages (RPMs), monocytes, and CD11b+ DCs, but not plasma-
cytoid DCs (pDCs) (Figures S5A and S5B). Monocyte-macro-268 Immunity 43, 264–276, August 18, 2015 ª2015 Elsevier Inc.phage-DC-specific POP1 expression was also observed in
other tissues, with no detectable expression in CD45– cells
(Figure S5C and data not shown). Collectively, these results
demonstrate POP1 expression in the monocyte-macrophage-
DC lineage.
Caspase-11 is responsible for LPS- and Gram-negative-
bacteria-induced lethal shock, but ASC and NLRP3 are both
Figure 4. Monocyte-Macrophage-DC-Specific Expression of POP1 Ameliorates LPS-Induced Peritonitis
(A) Analysis of POP1 expression by flow cytometry in peripheral blood cell populations fromwild-type (WT) and CD68-POP1 (POP1) mice. Data are representative
of three replicates.
(B) Quantification of MPO activity by in vivo imaging in mice 3 hr after i.p. injection of PBS or E. coli LPS (2.5 mg/kg body weight) in WT (n = 6) and CD68-POP1
(n = 5) mice.
(C and D) Endotoxic shock was induced by i.p. injection of E. coli LPS (20 mg/kg body weight) and body temperature (C) and survival (D) was determined in WT
(n = 5) and CD68-POP1 (n = 5) mice.
(E) ELISA of IL-1b and TNF-a in the serum of WT (n = 5) and CD68-POP1 (n = 5) mice 3 hr after i.p. E. coli LPS challenge (20 mg/kg body weight).
*p = 0.0036 by two-tailed unpaired t test in (B); *p < 0.005, **p < 0.005 by two-way ANOVA+Bonferoni posttest in (C); *p < 0.005 by asymmetrical Log-rankMantel-
Cox survival test in (D); *p = 0.0392 by two-tailed unpaired t test in (E); error bars represent SEM. See also Figures S3–S5.necessary for amplifying this response to LPS in vivo (Kayagaki
et al., 2011). Accordingly, Pycard/ and Nlrp3/ mice are
protected from LPS-induced lethality in response to moderate
LPS doses (Mariathasan et al., 2004, 2006; Kayagaki et al.,
2011). NLRP3 inflammasome-released IL-1b is essential for
neutrophil recruitment during sterile inflammation (McDonald
et al., 2010). Therefore, we injected WT and CD68-POP1 TG
mice i.p. with a low dose of LPS and determined neutrophil
infiltration 3 hr after LPS challenge by quantifying myeloperox-
idase (MPO) activity in vivo. Contrary to PBS, injection of LPS
recruited a substantial number of neutrophils into the perito-
neal cavity, which was completely abolished in CD68-POP1
TG mice (Figure 4B). Consequently, CD68-POP1 TG mice
experienced significantly less hypothermia (Figure 4C) and
were significantly more protected from a lethal LPS dose
(Figure 4D). Compared to 100% lethality in WT mice, only
30% of CD68-POP1 TG mice died within 96 hr, which is similar
to Pycard/ mice (Mariathasan et al., 2004). Consistent with
reduced neutrophil infiltration and increased survival, serum
IL-1b was reduced, but TNF-a levels remained unchanged
(Figure 4E), indicating that expression of POP1 in the mono-
cyte-macrophage-DC lineage is sufficient to impair inflamma-
some activation in response to PAMPs in vivo, thereby block-
ing the secretion of IL-1b and ameliorating an excessive host
response.Monocyte-Macrophage-DC-Specific Expression of
POP1 Ameliorates CAPS
Because sepsis is a rather complex disease, we investigated a
disease model, for which the pathology is absolutely dependent
on the NLRP3 inflammasome. Cryopyrinopathies (or Cryopyrin-
associated periodic syndromes; CAPS) are caused bymutations
in NLRP3 (Hoffman et al., 2001), are therefore directly linked to
the NLRP3 inflammasome, and can be recapitulated in mice
by knocking-in CAPS-associated NLRP3 mutations (Brydges
et al., 2009, 2013; Meng et al., 2009). We employed a mouse
model for Muckle Wells syndrome (MWS), where floxed
Nlrp3A350V, corresponding to human NLRP3A352V, is expressed
exclusively in myeloid cells in the presence of lysozyme M-Cre
(CreL) (Brydges et al., 2009, 2013). Nlrp3A350V/+ CreL mice
develop systemic inflammation that affects multiple organs,
display characteristic skin inflammation, and die within 2 weeks
of birth. This phenotype is caused by excessive IL-1b and IL-18
release as well as pyroptosis (Brydges et al., 2009, 2013).
Nlrp3A350V/+ CreL mice had inflammatory skin abscesses and le-
sions shortly after birth, which developed into scaling erythema
(Brydges et al., 2009), but Nlrp3A350V/+ CreL CD68-POP1 mice
did not display this phenotype (Figure S6A). Histological analysis
revealed that POP1 expression prevented leukocytic infiltrates in
multiple organs, including the liver and the skin, and also
restored skin architecture (Figure 5A). Also, the systemic IL-1bImmunity 43, 264–276, August 18, 2015 ª2015 Elsevier Inc. 269
Figure 5. Monocyte-Macrophage-DC-Specific Expression of POP1 Ameliorates CAPS
(A) H&E staining of skin sections at day 8 in Nlrp3A350V/+ CreL CD68-POP1 and Nlrp3A350V/+ CreL mice. Scale bars represent 100 mm (original) and 10 mm
(magnification).
(B) Serum IL-1b levels in 8-day-old Nlrp3A350V/+ CreL (n = 4) and Nlrp3A350V/+ CreL CD68-POP1 (n = 5) mice.
(C) Body weight of WT (n = 15), Nlrp3A350V/+ CreL CD68-POP1 (n = 11), and Nlrp3A350V/+ CreL (n = 11) mice.
(D) Survival of WT (n = 11), Nlrp3A350V/+ CreL CD68-POP1 (n = 10), and Nlrp3A350V/+ CreL (n = 8) mice.
(E) POP1mRNA expression (relative to control) in whole blood drawn from healthy controls (n = 23), CINCA (n = 2), and MWS (n = 5) patients (GEO: GSE40561).
Data are representative of two replicates in (A); error bars represent SEM. *p = 0.0394 in (B); *p < 0.005 by non-linear regression fit and Kruskal-Wallis one-way
ANOVA (p = 0.0021) with Dunn’s Multiple Comparison post test in (C); *p < 0.0001 by asymmetrical Log-rank Mantel-Cox survival test in (D); *p = 0.0359 by
two-tailed unpaired t test (E). See also Figures S6A and S6B.levels were reduced (Figure 5B). Significantly, POP1 expression
rescued the severe growth delay (Figure 5C) and preventedmor-
tality of Nlrp3A350V/+ CreL mice from multi-system organ failure
(Figure 5D). Because expression of POP1 efficiently ameliorated
CAPS, we analyzed POP1 expression in a previously published
patient cohort (Boissonet al., 2012) and found thatCAPSpatients
displayed significantly lower POP1 expression compared to
healthy controls (Figure 5E). We also observed the same trend
in leukocytes from two large, independent septic patient cohorts,
when compared to healthy controls (Figure S6B; Tang et al.,
2008;Wong et al., 2009), although the reduced POP1 expression
in patients was less pronounced. These findings demonstrate
that POP1 inhibits excessive NLRP3 inflammasome activity
in vivo and thereby ameliorates auto-inflammatory disease. We
also identified reducedPOP1expression inCAPSpatients,which
might circumvent appropriate inflammasome control.
POP1 Prevents ASC Particle Release and Ameliorates
ASC Particle-Induced Inflammation
Recently, polymerized ASC particles were detected in the
serum of active CAPS patients (Baroja-Mazo et al., 2014),270 Immunity 43, 264–276, August 18, 2015 ª2015 Elsevier Inc.which are released from macrophages through inflamma-
some-dependent pyroptosis and act as danger signals on
neighboring cells (Baroja-Mazo et al., 2014; Franklin et al.,
2014). POP1 prevented ASC nucleation and the subsequent
ASC polymerization, caspase-1 activation, and pyroptosis,
which are all required for the ASC particle response. Hence,
culture supernatants from LPS-primed and nigericin- or ATP-
treated GFP THP-1 cells and WT BMDMs contained ASC,
but supernatants from GFP-POP1 THP-1 cells (Figure 6A) or
POP1 BMDMs (Figure 6B) did not contain any ASC. Particu-
larly, the release of polymeric ASC was inhibited by POP1
(Figure 6C). Extracellular ASC particles are phagocytized by
macrophage and activate caspase-1 in an NLRP3- and ASC-
dependent process (Baroja-Mazo et al., 2014; Franklin et al.,
2014). FACS-purified ASC-GFP particles (Figure S6C) induced
IL-1b release in LPS-primed GFP THP-1 cells, but not in GFP-
POP1 THP-1 cells (Figure 6D), suggesting that POP1 prevents
ASC nucleation downstream of NLRP3 activation. POP1 is an
ASC binding protein, which can be incorporated into ASCPYD
filaments (Figure S1F). This can result in reduced ASCCARD
density and subsequently prevent caspase-1 nucleation and
Figure 6. Expression of POP1 Prevents ASC Particle Release and Ameliorates ASC Particle-Induced Inflammation
(A) LPS-primed THP-1 cells expressing GFP or GFP-POP1 were treated with nigericin and released ASC determined by immunoblot in total cell lysates (TCL) and
culture supernatants (SN).
(B) Wild-type (WT) and POP1 BMDMs were treated with ATP and released ASC determined by immunoblot in TCL and SN.
(C) Immunoblot analysis of ASC polymerization in untreated or LPS/ATP-treated WT and POP1 BMDMs after cross linking of pellets (P) and in TCL.
(D) ASC-GFP particles were FACS purified and imaged by immunofluorescence microscopy, showing the characteristic filamentous structure. Scale bar rep-
resents 2 mm. Culture SN from THP-1 cells stably expressing GFP or GFP-POP1 were analyzed for IL-1b release by ELISA in LPS-primed cells before (Ctrl) and
after treatment with 1 3 103 FACS-purified ASC-GFP particles.
(E) Mixed ASC-GFP/RFP-POP1 particles were FACS purified as above, showing comparable size and overall structure. Scale bar represents 2 mm. Culture SN
from THP-1 cells were analyzed for IL-1b release by ELISA in LPS primed cells before (Ctrl) and after treatment with 1 3 103 FACS-purified ASC-GFP and
ASC-GFP/RFP-POP1 particles.
(F) Quantification of MPO activity by in vivo imaging in WT and CD68-POP1 mice 4 hr after i.p. injection of PBS or 1 3 105 FACS-purified ASC-GFP particles
(n = 2/genotype).
(G) ELISA of total IL-1b in the peritoneal cavity from above mice 4 hr after ASC-GFP particle challenge.
(H) 30 min after i.p. injection of TAT-GFP or TAT-POP1 (40 mg/kg), mice were i.p. injected with LPS (2.5 mg/kg). After 1 hr, MPO activity was determined by in vivo
imaging and the MPO luminescent signal quantified in LPS-injected WT mice pre-treated with TAT-GFP (n = 2) and TAT-POP1 (n = 3) mice.
Data are representative of two (A–E) replicates; error bars represent SEM. *p = 0.0488 in (D); *p = 0.0022 in (E); *p = 0.0488 in (F); *p = 0.0038 in (G); all two-tailed
unpaired t test. See also Figures S6C–S6E.activation (Lu et al., 2014). To directly prove that POP1 incorpo-
ration into ASC particles renders them inactive, we generated
mixed ASC-GFP/RFP-POP1 particles (Figure S6C), which, in
contrast to ASC-GFP particles, failed to cause IL-1b release
in THP-1 cells (Figure 6E). Importantly, i.p. injection of ASC-
GFP particles into WT mice resulted in neutrophil recruitment
(Figure 6F) and IL-1b release (Figure 6G), which was substan-
tially reduced in CD68-POP1 TG mice.
Based on the reduced POP1 expression in CAPS patients
and its inflammasome inhibitory function in macrophages, we
designed a proof-of-concept treatment approach targeting
ASC inflammasomes. Cell-penetrating peptides are frequently
employed for the delivery of molecules targeting intracellularsignaling pathways (Schwarze et al., 1999), and so we pro-
duced recombinant POP1 and GFP as a control fused to the
cell-penetrating HIV TAT sequence (TAT-POP1 and TAT-GFP)
(Figure S6D). TAT-GFP was efficiently taken up by PMs after
i.p. injection in vivo (Figure S6E), and injection of TAT-POP1,
but not TAT-GFP, ameliorated LPS-induced peritonitis (Fig-
ure 6H), reminiscent to transgenic POP1 expression. Collec-
tively, these data show that POP1 also blocks the release of
ASC danger particles and consequently propagation of sec-
ondary inflammasome responses in neighboring cells and
that delivery of POP1 might be used as the basis for future
therapeutic approaches in patients with CAPS and other
inflammasomopathies.Immunity 43, 264–276, August 18, 2015 ª2015 Elsevier Inc. 271
Figure 7. POP1 Expression Is Regulated by
TLRs and IL-1b
(A) POP1 and HMGB1 transcripts were measured
by real-time PCR in LPS-treated primary human
macrophages.
(B) POP1 and PYCARD mRNA expression in leu-
kocytes from LPS-infused human subjects.
(C) POP1 mRNA expression in primary human
macrophages after 4 hr IL-1b treatment.
Data are representative of two (A, C, D) and
eight (B) replicates; error bars represent SEM.
*p = 0.0097, **p = 0.0443 (A); *p = 0.0284 (B); and
*p = 0.0266 (C); all two-tailed unpaired t test. See
also Figure S7.POP1 Functions in an Inducible Inflammasome
Regulatory Loop
Overwhelming evidence supports the necessity for a balanced
inflammasome response to maintain tissue homeostasis (He-
nao-Mejia et al., 2012). Therefore, we hypothesized that POP1
expression needs to be tightly regulated. We observed LPS-
induced late response gene expression of POP1 in human
macrophages (Figure 7A) and THP-1 cells (Figure S7A), but in
contrast to POP3, POP1 was not upregulated in response to
IFN-b (Khare et al., 2014), which emphasizes the distinct function
of individual POPs. Notably, POP1 expression peaked right
before the inducible expression of HMGB1, which is released
through pyroptosis (Lamkanfi et al., 2010; Willingham et al.,
2009) and contributes to inflammatory disease (Harris et al.,
2012). Thus, the late response expression of POP1 potentially
enables inflammasome functions in early host defense andmight
provide a mechanism to counter excessive release of late medi-
ators that perpetuate systemic inflammation, such as HMGB1.
Importantly, this LPS-inducible expression of POP1 was also
observed in leukocytes isolated fromhuman subjects after in vivo
LPS infusion (Figure 7B; Calvano et al., 2005). TLR4 is required
for inducible POP1 expression by LPS, as indicated by the fact
that a TLR4 inhibitor reduced POP1 expression (Figure S7B).
TLR signaling leads to NF-kB activation and blocking NF-kB
also reduced POP1 transcription (Figure S7B). Inducible POP1
transcription was caused not only by TLR4, but also by TLR2
activation by Pam3CSK4 (Figure S7C). IL-1R and IL-18R share
signaling components with TLRs and accordingly POP1 expres-
sion was also elevated in human macrophages after IL-1b
(Figure 7C) and IL-18 (Figure S7D) treatment. Thus, TLR, IL-1R,
and IL-18R engagement contributes to NF-kB-dependent
inducible transcription of POP1. At the transcriptional level, we
observed 4-fold increased POP1 expression in human macro-
phages after TLR or IL-1R stimulation and our stable GFP-POP1
THP-1 and Myc-POP1 THP-1 cells showed 3-fold and 7-fold
more POP1 compared to baseline expression levels, respec-
tively (Figures 1E, S1A, and S1E). Hence, our stable cell lines
closely mimicked the induced POP1 expression levels, which
were therefore also sufficient to impair inflammasome activity.
At the protein level, POP1 PM expressed less POP1 than GFP-
POP1 THP-1, as determined by flow cytometry and immunoblot
(Figure S7E), indicating that POP1 expression in our TG mice
was decreased relative to human macrophages. Still, we found
that POP1 expression levels in CD68-POP1 TG mice varied
slightly and correlated inversely with inflammasome activity, as272 Immunity 43, 264–276, August 18, 2015 ª2015 Elsevier Inc.determined by measuring IL-18 levels 4 hr after i.p. LPS injection
(R2 = 0.9316) (Figure S7F). Overall, our results demonstrate that
POP1 regulates the inflammasome-mediated IL-1b and IL-18
release, which in turn regulates POP1 expression.
DISCUSSION
ASC-containing inflammasomes are responsible for cytokine
release through canonical and non-canonical inflammasomes
(Mariathasan et al., 2004; Kayagaki et al., 2011, 2013) and
consequently play a central role in facilitating the beneficial in-
flammatory responses to clear pathogen infections and initiate
wound healing after tissue damage. However, uncontrolled in-
flammasome responses cause inflammatory disease through
excessive cytokine release (Strowig et al., 2012; Hoffman and
Brydges, 2011). Thus, a well-balanced inflammasome response
is crucial for maintaining homeostasis. Therefore, inflammasome
regulatory proteins probably exist to maintain an appropriate
level of activity and in particular to limit inflammasome activity
during the resolution phase of these responses. We proposed
that POP1 is one of these proteins. Assembly of the inflamma-
some platform is initiated by nucleation of ASC through PYD in-
teractions with PYD-containing PRRs followed by prion-like ASC
self-polymerization (Cai et al., 2014; Franklin et al., 2014; Lu
et al., 2014; Chu et al., 2015). Hence, the PYD plays a crucial
role in inflammasome assembly. We recently demonstrated
that POP3 selectively regulates ALR inflammasomes by binding
to the PYD of ALRs but not to ASC, which is sufficient to
prevent ALR-ASC interactions (Khare et al., 2014). In contrast
to POP3, our data support a model where POP1 acted more
broadly by binding to the ASCPYD, which prevented ASC interac-
tion with PYD-containing PRRs and consequently the crucial
ASC nucleation event. Similarly, POP1 prevented exogenous
ASC particle responses, which are only partially dependent on
NLRP3, but depend on ASC-nucleated ASC polymerization
(Cai et al., 2014; Franklin et al., 2014; Lu et al., 2014). Moreover,
mixed particles composed of ASC and POP1 were inactive,
probably by reducing the necessary ASC-CARD density
required for caspase-1 activation. Thus, POP1 expression pre-
vented not only inflammasome assembly and cytokine release,
but also release of ASC danger particles and propagation of sec-
ondary inflammasome responses to bystander cells. Previous
studies suggested that POP1 enhances IL-1b release in vitro
(Stehlik et al., 2003b). However, based on our results, this is
probably a consequence of overexpression in HEK293 cells,
because we also observed a weak nucleation of ASC polymeri-
zation by POP1 in these cells. Other PYDs, including PYD from
NLRP3, can also induce weak nucleation of ASC polymerization
in this cell type (Lu et al., 2014), and the NLRP3PYD also binds to
the same ASC region as POP1 (Vajjhala et al., 2012).
Overexpression studies of several PYD proteins in HEK293
cells have implicated PYDs in NF-kB regulation, but these results
were not observed in macrophages and in vivo. Similarly, we
previously observed an inhibitory effect of POP1 on NF-kB activ-
ity in HEK293 cells (Stehlik et al., 2003b) but did not observe
such activity in THP-1 cells, human macrophages, or BMDMs
in response to all tested stimuli. However, POP1-expressing
THP-1 cells showed a slightly reduced IkBa phosphorylation
in response to LPS, but this cannot be responsible for the potent
inhibition of caspase-1 and we did not observe significant
altered transcription of inflammasome components or release
of IL-6 and TNF-a. Filament formation of prion activity containing
signaling components is one of the mechanisms of innate
immune pathway activation. Although ASCPYD, AIM2PYD, and
NLRP3PYD contain such intrinsic prion activity (Lu et al., 2014;
Cai et al., 2014), POP1 does not appear to have this activity,
because it does not form these characteristic filaments (Stehlik
et al., 2003b), but POP1 expression levels probably are crucial
for its inflammasome inhibitory function. Inflammasome activity
increased upon POP1 silencing in human macrophages and
THP-1 cells but decreased upon stable expression of POP1 at
levels that are comparable to its induced endogenous expres-
sion levels. POP1 transgene expression in mice was lower than
in our stable cells and by extension also probably lower than in
human macrophages, and therefore closely mimicked physio-
logically relevant POP1 levels. Despite this lower expression,
POP1 was still able to inhibit the inflammasome, and variable
POP1 expression levels in individual TG mice even correlated
with its inflammasome inhibitory activity. An earlier study map-
ping the interaction of ASC with NLRP3 did not observe reduced
NLRP3-ASC interaction in the presence of POP1 when using
in vitro binding assays with recombinant proteins (Vajjhala
et al., 2012). However, protein folding and posttranslational
modifications might not be recapitulated in vitro and might
yield different results compared to our studies of endogenous
inflammasome assembly in human and mouse macrophages.
Posttranslational modifications, such as ubiquitination (Py
et al., 2013) and phosphorylation (Lin et al., 2015; Hara et al.,
2013), have been implicated in NLRP3 inflammasome activity,
and POP1 phosphorylation (Stehlik et al., 2003b) might also be
involved in the binding mechanism.
Excessive and uncontrolled release of inflammasome me-
diators contributes to auto-inflammatory and auto-immune dis-
eases (Strowig et al., 2012). Hence, blocking IL-1b has proved
beneficial in various inflammatory diseases in human and mice
(Dinarello, 2011). Furthermore, oligomeric ASC particles have
been identified in CAPS and pulmonary disease (Franklin et al.,
2014; Baroja-Mazo et al., 2014). Despite the tight regulation of in-
flammasome responses, even a single point mutation in NLRP3
can drive excessive systemic inflammation (Hoffman and
Brydges, 2011). Thus, inflammasome regulatory mechanisms
might also be impaired. In line with this possibility, we observed
reduced POP1 expression in CAPS patients. This observation
suggested that in addition to uncontrolled activation of NLRP3,recruitment and oligomerization of ASC and extracellular
release of ASC danger particles proceed uncontrolled, due to
reduced POP1 expression. The presence of POP1 might also
increase the required threshold for inflammasome assembly.
At low expression levels, as observed in resting macrophages,
POP1 would probably not interfere with acute host defense
and maintenance of metabolic health. However, upon inducible
expression as a late response gene, POP1 might become
involved in the resolution phase of inflammasome responses
(Figure S7G), which is still poorly understood. In particular,
POP1 expression before the onset of HMGB1 expression might
be important, because inflammasome-dependent release of
HMGB1 is directly linked to inflammatory disease (Yang et al.,
2013). Accordingly, in mice that normally lack POP1 and other
POP members (Stehlik and Dorfleutner, 2007; Khare et al.,
2014), POP1 expression potently ameliorated systemic inflam-
masome-driven inflammation. Interestingly, CAPS is caused
not only by excessive IL-1b secretion, but also by IL-18 secretion
and pyroptosis (Brydges et al., 2009, 2013). Furthermore, ASC
inflammasomes are also responsible for cytokine release by
the non-canonical inflammasome (Kayagaki et al., 2011). By
blocking all inflammasome-dependent mediators, POP1 ex-
hibited a potent anti-inflammatory function in peritonitis,
sepsis, and CAPS, and this function can probably be extended
to other ASC-dependent inflammatory diseases. Employing a
cell-permeable recombinant POP1 provided proof of concept
that a POP1-based therapy could be effective in CAPS and other
inflammasomopathy patients with impaired POP1 expression,
where it might function as a novel broad-spectrum anti-inflam-
matory treatment strategy targeting all inflammasome effectors.
Assembly of inflammasomes is not limited to macrophages,
but the cell types that are responsible for systemic inflammation
have not been elucidated yet. We demonstrated that mono-
cyte-macrophage-DC-lineage-specific expression of POP1
was sufficient to prevent systemic inflammation in three different
inflammatory disease models, which strongly implicates that in-
flammasome activation and defects in inflammasome control in
this lineage are crucial for promoting systemic inflammation.
Many studies highlight the importance of inflammasomes for
homeostasis and disease pathology and suggest that under-
standing the mechanism by which healthy tissues put the brakes
on inflammasome-induced systemic inflammation will be the
next important step for designing future therapies. With the re-
sults from our study, we started to provide some answers to
this important question. POP1 provides a unique mechanism
that evolved in humans to possibly allow tighter control of an
essential host defense system by guarding against excessive
and out-of-control responses that cause inflammatory disease.EXPERIMENTAL PROCEDURES
Animals
B6.TgN(CD68-POP1) TG mice were generated as described with GFP-POP1
(Khare et al., 2014; Iqbal et al., 2014). C57BL/6 wild-type (WT) and Lysozyme
M-Cre knock-in mice (CreL) were obtained from the Jackson Laboratories and
Nlrp3/, Pycard/, and floxedNlrp3A350V knock-in mice were described pre-
viously (Mariathasan et al., 2004, 2006; Brydges et al., 2009). Mice were
housed in a specific-pathogen-free animal facility and all experiments were
performed on age- and gender-matched, randomly assigned 8- to 14-week-
old mice conducted according to procedures approved by the NorthwesternImmunity 43, 264–276, August 18, 2015 ª2015 Elsevier Inc. 273
University Committee on Use and Care of Animals. Floxed Nlrp3A350V mice
(Brydges et al., 2009, 2013) were crossed with CreL and CD68-POP1 TG
mice and male and female offspring were analyzed for body weight and sur-
vival. Histological analysis was performed at day 8 after birth.
Macrophage Isolation, Culture, and Transfection
Peripheral blood-derived human macrophages, BMDMs, and peritoneal mac-
rophages (PMs) were isolated as described (Khare et al., 2012, 2014).
Quantitative Real-Time PCR
Total RNA was isolated and analyzed as described (Khare et al., 2012, 2014).
LPS-Induced Peritonitis
8- to 12-week-old female WT and CD68-POP1 TG mice had their abdomen
shaved under anesthesia and were randomly selected for i.p. injection with
PBS or LPS (2.5 mg/kg, E. coli 0111:B4, Sigma). After 3 hr, mice were i.p. in-
jected with XenoLight Rediject Inflammation probe (200 mg/kg, PerkinElmer)
(Gross et al., 2009) and in vivo bioluminescence was captured by imaging
(IVIS Spectrum, PerkinElmer) 10 min after injection with a 5 min exposure on
anesthetized mice (Khare et al., 2014). Images were quantified with Living Im-
age software (PerkinElmer). Endotoxic shock was induced by i.p. injection of a
lethal dose of 20 mg/kg LPS (E. coli 0111:B4) and mice were monitored four
times daily for survival. Body temperature was measured with an animal rectal
probe. Blood was collected 3 hr after LPS injection by mandibular bleed, and
serum cytokine levels were quantified by ELISA.
ASC-Particle-Induced Peritonitis
ASC-GFP-containing particles were FACS purified and verified by micro-
scopy. 14-week-old male WT and CD68-POP1 TG mice had their abdomen
shaved under anesthesia and were randomly selected for i.p. injection with
PBS or FACS-purified ASC-GFP particles (1 3 105 particles/mouse). After
4 hr, MPO activity was determined as above. Peritoneal lavage fluids were
collected and assayed for IL-1b by ELISA.
Plasmids
pcDNA3 and pGEX-based expression constructs for ASC, POP1, NLRP3,
ASCPYD, and NLRP3PYD were described earlier (Khare et al., 2014; Stehlik
et al., 2003a, 2003b).
Antibody-Based Detection
Co-immunoprecipitations (IP), GST pull down, ASC cross-linking, immunohis-
tochemistry, ELISA, flow cytometry, and caspase-1 activity were performed as
previously described (Khare et al., 2014; Fernandes-Alnemri and Alnemri,
2008).
Cell-Penetrating Recombinant Proteins
6xHIS-POP1 and a 6xHIS-GFP cDNAs were fused with the HIV TAT sequence
and purified from E. coli. 12-week-old male WT mice had their abdomen
shaved under anesthesia were randomly selected for i.p. injection with TAT-
GFP or TAT-POP1 (40 mg/kg) for 30 min prior LPS i.p. injection (2.5 mg/kg,
E. coli 0111:B4, Sigma) and were quantified for MPO activity in vivo 1 hr later,
as described above.
Statistics
Graphs represent the mean ± SEM. A standard two-tailed unpaired t test was
used for statistical analysis of two groups with all data points showing a normal
distribution and Kaplan-Meier survival curves were used to investigate differ-
ences in survival. Values of p < 0.05 were considered significant and listed in
the figure legends (Prism 5, GraphPad). The investigators were not blinded to
the genotype of themice/cells. Sample sizeswere selected on the basis of pre-
liminary results to ensure a power of 80% with 95% confidence between
populations.
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